Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Azah Borham"'
Autor:
Hannah Dzimitrowicz, Elizabeth Esterberg, LaStella Miles, Giovanni Zanotti, Azah Borham, Michael R. Harrison
Publikováno v:
Cancer Medicine, Vol 10, Iss 24, Pp 8891-8898 (2021)
Abstract Background It is unclear whether patients with renal cell carcinoma (RCC) are routinely assessed for recurrence risk post‐nephrectomy and whether patients at high recurrence risk are seen by providers who can evaluate candidacy for adjuvan
Externí odkaz:
https://doaj.org/article/6932471d1f104377b8b3309cf1069065
Autor:
Christos Kyriakopoulos, Nrupen A. Bhavsar, Michael R. Harrison, Walter M. Stadler, Ulka N. Vaishampayan, Azah Borham, Brant A. Inman, Benjamin A. Gartrell, Mayer Fishman, Jack Mardekian, Daniel J. George, Sumanta K. Pal, Thomas E. Hutson, Che-Kai Tsao, Christopher W. Ryan, Brian A. Costello, Heather S.L. Jim, Leonard Joseph Appleman, Arif Hussain, Ana M. Molina, Hans J. Hammers, Russell K. Pachynski, Yousef Zakharia, Neeraj Agarwal
Publikováno v:
Cancer. 127:2204-2212
Background Systemic therapy (ST) can be deferred in patients who have metastatic renal cell carcinoma (mRCC) and slow-growing metastases. Currently, this subset of patients managed with active surveillance (AS) is not well described in the literature
Autor:
Elizabeth Esterberg, LaStella Miles, Hannah Dzimitrowicz, Giovanni Zanotti, Michael R. Harrison, Azah Borham
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 24, Pp 8891-8898 (2021)
Cancer Medicine, Vol 10, Iss 24, Pp 8891-8898 (2021)
Background It is unclear whether patients with renal cell carcinoma (RCC) are routinely assessed for recurrence risk post‐nephrectomy and whether patients at high recurrence risk are seen by providers who can evaluate candidacy for adjuvant systemi
Autor:
Brian A. Costello, Arif Hussain, Hans J. Hammers, Daniel J. George, Michael R. Harrison, Nrupen A. Bhavsar, Mayer Fishman, Heather S.L. Jim, Neeraj Agarwal, Azah Borham, Yousef Zakharia, Thomas E. Hutson, Walter M. Stadler, Sumanta K. Pal, Christos Kyriakopoulos, Russell K. Pachynski, Christopher W. Ryan, Che Kai Tsao, Ulka N. Vaishampayan, Benjamin A. Gartrell, Ana M. Molina, Jack Mardekian, Leonard Joseph Appleman
Publikováno v:
Clinical genitourinary cancer. 20(1)
Introduction : The Metastatic Renal Cell Carcinoma (MaRCC) Registry provides prospective data on real-world treatment patterns and outcomes in patients with metastatic renal cell carcinoma (mRCC). Methods and Materials : Patients with mRCC and no pri
Publikováno v:
Blood. 136:28-29
Introduction: Systemic amyloidoses are progressive, life-threatening diseases characterized by the deposition of amyloid protein fibrils of varying origin in different tissues/organ systems (Merlini G, et al. N Engl J Med 2003;349:583-96). The precur
Autor:
Daniel J. George, Patricia Creel, Greg Samsa, Azah Borham, Bradford R. Hirsch, Nrupen A. Bhavsar, Michael R. Harrison, Ronit Simantov, Amy P. Abernethy, S. Wolf
Publikováno v:
Cancer Investigation. 35:333-344
The Metastatic Renal Cell Cancer Registry, a large, nationally representative, prospective registry of patients with metastatic renal cell carcinoma (mRCC), aims to understand real-world treatment patterns and outcomes of patients with mRCC in routin
Autor:
Hannah Dzimitrowicz, Giovanni Zanotti, Elizabeth Esterberg, Michael R. Harrison, LaStella Miles, Azah Borham
Publikováno v:
Journal of Clinical Oncology. 38:636-636
636 Background: It is unclear whether post-nephrectomy patients with renal cell carcinoma (RCC) in real-world practice settings are typically assessed for recurrence risk post-operatively and whether patients at high risk of recurrence are seen by pr
Autor:
Nrupen A. Bhavsar, Steven Wolf, Ulka N. Vaishampayan, Christos Kyriakopoulos, Sumanta K. Pal, Che-Kai Tsao, Hans J. Hammers, Michael R. Harrison, Arif Hussain, Daniel J. George, Azah Borham, Heather S.L. Jim, Brian A. Costello, Walter M. Stadler, Leonard Joseph Appleman
Publikováno v:
Journal of Clinical Oncology. 34:e16097-e16097
e16097Background: In the past decade, 8 regimens were approved for metastatic renal cell carcinoma (mRCC) leading to a quickly changing clinical landscape. Trials addressing treatment (tx) efficacy...
Autor:
Sumanta K. Pal, Che-Kai Tsao, Arif Hussain, Nrupen A. Bhavsar, Daniel J. George, Steven Wolf, Heather S.L. Jim, Hans J. Hammers, Ulka N. Vaishampayan, Michael R. Harrison, Azah Borham, Christos Kyriakopoulos, Walter M. Stadler, Leonard Joseph Appleman, Brian A. Costello
Publikováno v:
Journal of Clinical Oncology. 34:e16084-e16084
e16084Background: Metastatic renal cell carcinoma (mRCC) is a heterogeneous disease, often presenting with an indolent course. Our prior retrospective work indicates many patients (pts) may not rec...
Autor:
Patricia Creel, Nrupen A. Bhavsar, Brian A. Costello, Walter M. Stadler, Daniel J. George, Ulka N. Vaishampayan, Azah Borham, Hans J. Hammers, Steven Wolf, Kathleen A. Johnson, Leonard Joseph Appleman, Michael R. Harrison, Greg Samsa, Christos Kyriakopoulos, Eric M. Richardson
Publikováno v:
Journal of Clinical Oncology. 34:563-563
563 Background: Clinical trials mRCC pts are different from real world pts, resulting in bias in the literature. The MaRCC Registry is designed to survey questions not asked in tri als, such as why physicians make certain management decisions. This a